Jiya, masana daga FDA (Hukumar Abinci da Magunguna) sun bincika lamarin IQOS, shahararren tsarin taba sigari Philip Morris. Kuma kamar yadda aka ce FDA ba ta yi jinkirin yanke shawara kan wurin da ke bayyana cewa Philip Morris bai nuna sarai cewa na'urarsa ta rage haɗarin kamuwa da cuta ba.
BABU RAGE HADARI TARE DA PHILIP MORRIS IQOS!
Idan ra'ayin FDA kawai shawara ne kuma ba lallai ba ne ya yi kira a cikin tambaya yiwuwar tallan samfurin a cikin 'yan watanni, gaskiyar ta kasance cewa sakamakon da aka bayyana ya kasance mara kyau. Tabbas, a cewar kwamitin ba da shawara na Hukumar Lafiya ta Tarayya (FDA) wanda ya gana a jiya Philip Morris International bai kamata a bari ya yi ikirarin cewa na'urar ta ta iQOS mai zafi na iya rage haɗarin cututtukan da ke da alaƙa da shan taba.
Wannan kwamiti ya yi la'akari da cewa Philip Morris bai nuna cikakkiyar cewa na'urarsa tana rage haɗarin cututtuka ba. Ya kuma yi watsi da ikirarin cewa amfani da wannan na'urar ba shi da haɗari fiye da ci gaba da shan taba.
Komitin ya amince da da'awar Philip Morris na cewa iQOS yana rage masu amfani da shi ga sinadarai masu cutarwa ko masu illa ga masu shan taba wadanda suka daina shan taba gaba daya. Amma kamfanin taba sigari bai tabbatar da cewa raguwar wannan fallasa ya haifar da ingantacciyar hanya mai yuwuwa a cikin ma'auni da raguwar mace-mace ba.
A halin yanzu, wannan sanarwar ta yi tasiri mai karfi a kasuwannin hannayen jari Philip Morris wanda ya yi asarar fiye da 6% kafin ya shafe wani ɓangare na asararsa da kuma sanya raguwar 2,1% zuwa 108,28 daloli a 17: 47 pm GMT a Wall Street. Don ganin ko a cikin watanni masu zuwa na'urar za ta sami izinin tallace-tallace a Amurka ko a'a.
source : Bursorama
